Prometic secures $13.2 mln tranche from Thomvest affiliate
Laval, Québec-based biopharmaceutical company Prometic Life Sciences Inc (TSX: PLI) has secured an additional $13.2 million tranche from an affiliate of Thomvest Asset Management. The funding is linked to a $100 million line of credit established in 2017 with Thomvest, an investment vehicle of Canadian billionaire Peter Thomson. Prometic has two drug discovery platforms, small molecule therapeutics and plasma-derived therapeutics, focused on unmet medical needs in the field of fibrosis and orphan diseases. It previously raised financing from Thomvest Seed Capital and California Capital Equity.
28 February 2019•3 mins read
